Resmed Inc (NYSE: RMD) has reported earnings for its third fiscal quarter (ending March 31) of $2.04 versus $1.58 for the same period a year ago. For the latest four quarters through March 31, E.P.S. were $6.52 compared to $5.88 a year ago.
Recent Price Action
Resmed Inc (NYSE: RMD) stock closed at $183.42 on 4/25/24 after a slight decline of -0.2%. Trading volume in this decline was normal. The stock has risen 5.5% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, RMD is expected to continue to be a modest Value Builder.
Resmed has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Resmed has a very low Appreciation Score of 11 but a slightly positive Power Rating of 61, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment